Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men

Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men

Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors prevent cardiovascular complications in type 2 diabetes. We aimed to study whether they have similar effects in women and men by summarizing the effects of SGLT2 inhibitors compared to placebo on vascular and safety outcomes stratified by sex. We in...

Full description

Bibliographic Details
Main Authors:	Rådholm, K, Zhou, Z, Clemens, K, Neal, B, Woodward, M
Format:	Journal article
Language:	English
Published:	Wiley 2019

Similar Items

Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy plus /- oral agents in type 2 diabetes
by: Matthews, DR, et al.
Published: (2012)

Disparities in prescribing of sodium-glucose co-transporter-2 (SGLT2) inhibitors and DPP-4 inhibitors in people with Type 2 diabetes and chronic kidney disease (CKD)
by: Shah, S, et al.
Published: (2018)

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors
by: Herrington, WG, et al.
Published: (2021)

The effect of sodium‐glucose co‐transporter 2 inhibitors on outcomes after cardiac resynchronization therapy
by: Bray, JJ, et al.
Published: (2024)

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
by: Hinton, W, et al.
Published: (2021)

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
by: McGovern, A, et al.
Published: (2017)

Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
by: Hinton, W, et al.
Published: (2020)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
by: Herrington, W, et al.
Published: (2022)

Does renal function or heart failure diagnosis affect primary care prescribing for sodium-Glucose co-transporter 2 inhibitors in type 2 diabetes?
by: Hinton, W, et al.
Published: (2020)

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
by: Vasilakou, D, et al.
Published: (2013)

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol)
by: McGovern, A, et al.
Published: (2017)

Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
by: Vale, C, et al.
Published: (2024)

Prevalence of undiagnosed Type 2 diabetes and impaired fasting glucose in older British men and women.
by: Thomas, M, et al.
Published: (2005)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management
by: Katsiki, N, et al.
Published: (2017)

How generalizable are cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors? A national database study: study protocol
by: Hinton, W, et al.
Published: (2019)

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
by: Fletcher, RA, et al.
Published: (2024)

Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study
by: Forbes, AK, et al.
Published: (2024)

Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis
by: Patel, SM, et al.
Published: (2024)

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study
by: Chou, OHI, et al.
Published: (2024)

Intensive glucose control and macrovascular outcomes in type 2 diabetes.
by: Turnbull, F, et al.
Published: (2009)

A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population
by: Forbes, AK, et al.
Published: (2024)

Impaired insulin signal transduction and glucose transport in the type 2 diabetic heart
by: Desrois, M, et al.
Published: (2001)

Diabetes, glycated haemoglobin and the risk of myocardial infarction in women and men: a prospective cohort study of the UK Biobank
by: Woodward, M
Published: (2020)

UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (sglt-2) inhibition in adults with kidney disease 2023 update
by: Roddick, AJ, et al.
Published: (2023)

Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes.
by: Martin, J, et al.
Published: (1991)

Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart.
by: Desrois, M, et al.
Published: (2004)

Adverse differences in cardiometabolic risk factor levels between individuals with pre-diabetes and normal glucose metabolism are more pronounced in women than in men: the Maastricht Study
by: de Ritter, R, et al.
Published: (2019)

Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes
by: Marjot, T, et al.
Published: (2019)

SURFACE SEGREGATION AND SODIUM-TRANSPORT IN NAXCOO2
by: Kemp, J, et al.
Published: (1990)

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
by: Patel, A, et al.
Published: (2008)

Women develop diabetes at higher BMIs than men.
by: Sourij, H, et al.
Published: (2012)

Women develop diabetes at higher BMIs than men
by: Sourij, H, et al.
Published: (2012)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
by: Staplin, N, et al.
Published: (2021)

Postprandial glucose and its role in type 2 diabetes.
by: Davidson, J, et al.
Published: (2006)

Postprandial glucose and its role in type 2 diabetes.
by: Davidson, J, et al.
Published: (2006)

Prevalence of diabetes mellitus and impaired glucose tolerance in parents of women with gestational diabetes.
by: McLellan, J, et al.
Published: (1995)

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
by: Perkovic, V, et al.
Published: (2013)

Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE‐ON study
by: Rådholm, K, et al.
Published: (2018)

Diabetes in pregnancy: time to focus on women with type 2 diabetes
by: Hirst, JE, et al.
Published: (2021)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
by: Herrington, W, et al.
Published: (2018)